Update of green tea interactions with cardiovascular drugs and putative mechanisms

José Pablo Werba, Shingen Misaka, Monica Gianna Giroli, Kenju Shimomura, Manuela Amato, Niccolò Simonelli, Lorenzo Vigo, Elena Tremoli

Research output: Contribution to journalReview article

Abstract

Many patients treated with cardiovascular (CV) drugs drink green tea (GT), either as a cultural tradition or persuaded of its putative beneficial effects for health. Yet, GT may affect the pharmacokinetics and pharmacodynamics of CV compounds. Novel GT-CV drug interactions were reported for rosuvastatin, sildenafil and tacrolimus. Putative mechanisms involve inhibitory effects of GT catechins at the intestinal level on influx transporters OATP1A2 or OATP2B1 for rosuvastatin, on CYP3A for sildenafil and on both CYP3A and the efflux transporter p-glycoprotein for tacrolimus. These interactions, which add to those previously described with simvastatin, nadolol and warfarin, might lead, in some cases, to reduced drug efficacy or risk of drug toxicity. Oddly, available data on GT interaction with CV compounds with a narrow therapeutic index, such as warfarin and tacrolimus, derive from single case reports. Conversely, GT interactions with simvastatin, rosuvastatin, nadolol and sildenafil were documented through pharmacokinetic studies. In these, the effect of GT or GT derivatives on drug exposure was mild to moderate, but a high inter-individual variability was observed. Further investigations, including studies on the effect of the dose and the time of GT intake are necessary to understand more in depth the clinical relevance of GT-CV drug interactions.

Original languageEnglish
Pages (from-to)S72-S77
JournalJournal of Food and Drug Analysis
Volume26
Issue number2
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Cardiovascular Agents
green tea
Tea
drugs
tacrolimus
Tacrolimus
Nadolol
warfarin
Cytochrome P-450 CYP3A
drug interactions
Simvastatin
Warfarin
Drug Interactions
pharmacokinetics
transporters
Pharmacokinetics
drug toxicity
Catechin
pharmacology
flavanols

Keywords

  • Cardiovascular drugs
  • Green tea
  • Herb–drug interactions

ASJC Scopus subject areas

  • Food Science
  • Pharmacology

Cite this

Update of green tea interactions with cardiovascular drugs and putative mechanisms. / Werba, José Pablo; Misaka, Shingen; Giroli, Monica Gianna; Shimomura, Kenju; Amato, Manuela; Simonelli, Niccolò; Vigo, Lorenzo; Tremoli, Elena.

In: Journal of Food and Drug Analysis, Vol. 26, No. 2, 01.04.2018, p. S72-S77.

Research output: Contribution to journalReview article

@article{07f64335ecb44d139c69c943603bf46b,
title = "Update of green tea interactions with cardiovascular drugs and putative mechanisms",
abstract = "Many patients treated with cardiovascular (CV) drugs drink green tea (GT), either as a cultural tradition or persuaded of its putative beneficial effects for health. Yet, GT may affect the pharmacokinetics and pharmacodynamics of CV compounds. Novel GT-CV drug interactions were reported for rosuvastatin, sildenafil and tacrolimus. Putative mechanisms involve inhibitory effects of GT catechins at the intestinal level on influx transporters OATP1A2 or OATP2B1 for rosuvastatin, on CYP3A for sildenafil and on both CYP3A and the efflux transporter p-glycoprotein for tacrolimus. These interactions, which add to those previously described with simvastatin, nadolol and warfarin, might lead, in some cases, to reduced drug efficacy or risk of drug toxicity. Oddly, available data on GT interaction with CV compounds with a narrow therapeutic index, such as warfarin and tacrolimus, derive from single case reports. Conversely, GT interactions with simvastatin, rosuvastatin, nadolol and sildenafil were documented through pharmacokinetic studies. In these, the effect of GT or GT derivatives on drug exposure was mild to moderate, but a high inter-individual variability was observed. Further investigations, including studies on the effect of the dose and the time of GT intake are necessary to understand more in depth the clinical relevance of GT-CV drug interactions.",
keywords = "Cardiovascular drugs, Green tea, Herb–drug interactions",
author = "Werba, {Jos{\'e} Pablo} and Shingen Misaka and Giroli, {Monica Gianna} and Kenju Shimomura and Manuela Amato and Niccol{\`o} Simonelli and Lorenzo Vigo and Elena Tremoli",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.jfda.2018.01.008",
language = "English",
volume = "26",
pages = "S72--S77",
journal = "Journal of Food and Drug Analysis",
issn = "1021-9498",
publisher = "National Laboratories of Foods and Drugs",
number = "2",

}

TY - JOUR

T1 - Update of green tea interactions with cardiovascular drugs and putative mechanisms

AU - Werba, José Pablo

AU - Misaka, Shingen

AU - Giroli, Monica Gianna

AU - Shimomura, Kenju

AU - Amato, Manuela

AU - Simonelli, Niccolò

AU - Vigo, Lorenzo

AU - Tremoli, Elena

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Many patients treated with cardiovascular (CV) drugs drink green tea (GT), either as a cultural tradition or persuaded of its putative beneficial effects for health. Yet, GT may affect the pharmacokinetics and pharmacodynamics of CV compounds. Novel GT-CV drug interactions were reported for rosuvastatin, sildenafil and tacrolimus. Putative mechanisms involve inhibitory effects of GT catechins at the intestinal level on influx transporters OATP1A2 or OATP2B1 for rosuvastatin, on CYP3A for sildenafil and on both CYP3A and the efflux transporter p-glycoprotein for tacrolimus. These interactions, which add to those previously described with simvastatin, nadolol and warfarin, might lead, in some cases, to reduced drug efficacy or risk of drug toxicity. Oddly, available data on GT interaction with CV compounds with a narrow therapeutic index, such as warfarin and tacrolimus, derive from single case reports. Conversely, GT interactions with simvastatin, rosuvastatin, nadolol and sildenafil were documented through pharmacokinetic studies. In these, the effect of GT or GT derivatives on drug exposure was mild to moderate, but a high inter-individual variability was observed. Further investigations, including studies on the effect of the dose and the time of GT intake are necessary to understand more in depth the clinical relevance of GT-CV drug interactions.

AB - Many patients treated with cardiovascular (CV) drugs drink green tea (GT), either as a cultural tradition or persuaded of its putative beneficial effects for health. Yet, GT may affect the pharmacokinetics and pharmacodynamics of CV compounds. Novel GT-CV drug interactions were reported for rosuvastatin, sildenafil and tacrolimus. Putative mechanisms involve inhibitory effects of GT catechins at the intestinal level on influx transporters OATP1A2 or OATP2B1 for rosuvastatin, on CYP3A for sildenafil and on both CYP3A and the efflux transporter p-glycoprotein for tacrolimus. These interactions, which add to those previously described with simvastatin, nadolol and warfarin, might lead, in some cases, to reduced drug efficacy or risk of drug toxicity. Oddly, available data on GT interaction with CV compounds with a narrow therapeutic index, such as warfarin and tacrolimus, derive from single case reports. Conversely, GT interactions with simvastatin, rosuvastatin, nadolol and sildenafil were documented through pharmacokinetic studies. In these, the effect of GT or GT derivatives on drug exposure was mild to moderate, but a high inter-individual variability was observed. Further investigations, including studies on the effect of the dose and the time of GT intake are necessary to understand more in depth the clinical relevance of GT-CV drug interactions.

KW - Cardiovascular drugs

KW - Green tea

KW - Herb–drug interactions

UR - http://www.scopus.com/inward/record.url?scp=85042146500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042146500&partnerID=8YFLogxK

U2 - 10.1016/j.jfda.2018.01.008

DO - 10.1016/j.jfda.2018.01.008

M3 - Review article

AN - SCOPUS:85042146500

VL - 26

SP - S72-S77

JO - Journal of Food and Drug Analysis

JF - Journal of Food and Drug Analysis

SN - 1021-9498

IS - 2

ER -